Close mobile menu×
Close mobile menu

Henry N Ginsberg, MD

Board Certifications: 
Endocrinology, Diabetes and Metabolism, Preventive Medicine, Internal Medicine
Accepting New Patients
Profile Headshot

Schedule an Appointment

Phone Appointments

New and Existing Patients:

Connect Patient Portal

For existing patients, login to make an appointment, view documentation or contact your care provider.

Connect Sign In

Credentials & Experience

Board Certifications

  • Endocrinology, Diabetes and Metabolism
  • Preventive Medicine
  • Internal Medicine

Clinical Expertise

  • Cholesterol Management

Education & Training

  • State University of New York - Downstate Health Sciences Center
  • Internship: Boston City Hospital
  • Residency: Boston City Hospital
  • Fellowship: Stanford University Medical Center

Honors & Awards

  • Alpha Omega Alpha
  • 1981-1986 Public Health Service Research Career Development Award
  • 1981-1986 Irma T. Hirschl Career Scientist Award
  • 1984 Irvine H. Page Award: American Heart Association - Honorable Mention
  • 1986 American Society for Clinical Investigation
  • 1992 Mary Rose Swartz Invited Lectureship of the New York Dietetic Association
  • 1996 American Association of Physicians
  • 1996 David Rubenstein Lecture of the Canadian Lipid Club
  • 1997 Albert Hogan Memorial Lecture, University of Missouri
  • American Heart Association Special Recognition Award

About Henry Ginsberg

Academic Titles

  • Herbert and Florence Irving Professor of Medicine

Administrative Positions

  • Director Emeritus, Irving Institute for Clinical & Translational Research

Hospital Affiliations

  • NewYork-Presbyterian / Columbia University Irving Medical Center


  • Spanish


  • Male

Insurance Accepted


  • EPO
  • HMO
  • Medicare Managed Care
  • NYP Employee Plan
  • NY Signature
  • POS
  • PPO
  • Signature Administrators
  • Student Health


  • Medicare Managed Care
  • Special Needs Plan

Capital District Physician Health Plan

  • Capital District Physician Health Plan


  • EPO
  • Great West
  • HMO
  • POS
  • PPO


  • Medicare Managed Care
  • PPO


  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross/Blue Shield

  • EPO
  • Medicare Managed Care
  • PPO

Local 1199

  • Local 1199


  • MagnaCare

MVP Health Care

  • Child/Family Health Plus
  • Essential Plan
  • HMO
  • Medicaid Managed Care

Oxford Health Plans

  • Freedom
  • Liberty


  • Columbia University Employee Plan
  • Compass (Exchange)
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Contact & Locations

622 West 168th Street
Room 307
New York, New York 10032


Dr. Ginsberg conducts research related to the regulation of the levels and metabolism of apolipoprotein B-containing lipoproteins, the lipoproteins carrying triglycerides and the bulk of cholesterol in blood. These include the atherogenic very low density and low density lipoproteins.

Dr. Ginsberg has a particular emphasis on the pathophysiology of hypertriglyceridemia and the dyslipidemia associated with insulin resistance and diabetes mellitus. Research is conducted at three levels: tissue culture using both human and rat hepatoma cells, transgenic mice, and human clinical studies. In cultured cells, Dr. Ginsberg and his associates have described the role of lipid substrate availability in determining if newly synthesized a of degradation and lipoprotein assembly of apoB. His group has characterized the role of the proteasome in the degradation of apoB. In transgenic mice, he had developed a model of insulin resistance and dylipidemia with many characteristics of the human disorder. This model, as well as others now in use in the lab, allow the group to dissect the important components of substrate availability and genetic control that lead to hypertriglyceridemia. Dr. Ginsberg's group makes and studies transgenic mice, conducting whole body, cellular, and molecular experiments.

In clinical studies, Dr. Ginsberg is investigating postprandial hyperlipidemia as a risk factor in patients with diabetes. He is also part of a group at Columbia that will be studying the role of glycemic, lipid and blood pressure control in the prevention of cardiovascular disease in patients with diabetes. The latter, named the ACCORD trial, is a 10-year trial with 10,000 patients at 6 sites across the United States. Dr. Ginsberg also has a long record of research into the effects of diet on lipid and lipoprotein metabolism in humans, and has conducted numerous controlled feeding studies in humans.

Research Interests

  • Hypertriglyceridemia molecular/cellular regulation, in models of insulin resistance/diabetes

Selected Publications

  • Liang, J-s., Kim, T., Fang, S., Weissman, A.M., Fisher, E.A., and Ginsberg, H.N. (2003) Overexpression of the tumor autocrine motility factor receptor-gp78, a ubiquitin protein ligase (E3), results in increased ubiquitinylation and decreased secretion of apolipoprotein B100 in Hep G2 cells. J Biol Chem 278:23984-8
  • Ginsberg, H.N. and Fisher, E.A. (2002) Complexity in the secretory pathway: The assembly and secretion of apolipoprotein B-containing lipoproteins. J. Biol. Chem 277:17377-80
  • Siri P., Candela, N., Ko, C., Zhang Y., Eusufzai, S., Ginsberg, H.N., and Huang Li-Shin. (2001) Post-transcriptional stimulation of the assembly and secretion of triglyceride-rich apolipoproteinB-lipoproteins in a mouse with selective deficiency of brown adipose tissue, obesity and insulin resistance. J Biol Chem 276:46064-72
  • Liang, J-S., Distler, O., Cooper, D, Jamil, H., Deckelbaum, R.J., Ginsberg, H.N. and Sturley, S.J. (2001) HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: A potential mechanism for protease inhibitor-induced hyperlipidemia. Nature Medicine 7:1327-31
  • Mitchell, D.M., Zhou, M., Pariyarath, R. Wang, H., Aitchison, J.D. Ginsberg, H.N. and Fisher, E.A. (1998) Apoprotein B has a prolonged interaction with the translocon during which its lipidation and translocation changes from MTP-dependent to MTP-independent. Proc. Natl. Acad. Sci. USA. 95:14733-8
  • Zhou, M.Y., Fisher, E.A., Ginsberg, H.N. (1998) Regulatable co-translational ubiquitination of apolipoprotein B:100: A new paradigm for proteasomal degradation of a secretory protein. J. Biol. Chem. 38:24649-53